Title: The pharmacoeconomic appraisal of implantable cardioverter-defibrillator for the prevention of sudden cardiac death
- Arkadiusz Pietrasik, Maciej Niewada, Krzysztof J. Filipiak, Grzegorz Opolski
- type 5
- Polish Journal of Cardiology
- Start page:
- Final page:
- cost-effectiveness, cost of life year gained, ventricular tachyarrhytmias, implantable cardioverter-defibrillator
The results of randomized clinical trials have proved that implantable cardioverter defibrillators (ICDs) redu-ce the risk of death in survivors of ventricular tachyarrhythmias. High costs of ICD devices must limit their use to the subset of patients who would benefit most and for whom ICDs are morę effective and cost-effec-tive. The strategy for the identification of patients who could benefit from ICD is not clearly established. It has been postulated that the presence of two or morę risk factors (age >70years, left ventricular ejection fraction <35%, and New York Heart Association class III) may identify the patient who would benefit most from the ICD implantation resulting in cost-effective use of resources but further research in this field is still needed. The clinical trials and pharmacoeconomic analyses on cost-effectiveness of ICDs in therapy of li-ve-threatening ventricular tachyarrhythmias are reviewed in the paper.